tiprankstipranks
Bio-Path Holdings Provides 2024 Clinical and Operational Update
PremiumPress ReleasesBio-Path Holdings Provides 2024 Clinical and Operational Update
17d ago
Bio-Path price target raised to $40 from $12 at Roth MKM
PremiumThe Fly
Bio-Path price target raised to $40 from $12 at Roth MKM
23d ago
Bio-Path receives noncompliance letter from Nasdaq
PremiumThe Fly
Bio-Path receives noncompliance letter from Nasdaq
1M ago
Bio-Path reports FY23 EPS ($33.63) vs ($38.12) last year
PremiumThe FlyBio-Path reports FY23 EPS ($33.63) vs ($38.12) last year
1M ago
BPTH Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
BPTH Upcoming Earnings Report: What to Expect?
1M ago
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
PremiumPress Releases
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
2M ago
Bio-Path Holdings Approves Reverse Stock Split Vote
PremiumCompany AnnouncementsBio-Path Holdings Approves Reverse Stock Split Vote
3M ago
Bio-Path completes first dose escalation part of Phase 1 trial of BP1002
PremiumThe Fly
Bio-Path completes first dose escalation part of Phase 1 trial of BP1002
3M ago
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
PremiumPress Releases
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100